Obeticholic acid (OCA), Intercept Pharmaceuticals

Drug: Obeticholic acid (OCA)
Company: Intercept Pharmaceuticals
Phase: Phase III
Class: Farnesoid X receptor (FXR) agonist
2020 sales: $2.99 billion
Net present sales: $11.4 billion

Shares of Intercept Pharmaceuticals ($ICPT) went into overdrive at the beginning of the year, soaring more than 250% on the surprise news that a Phase IIb clinical study for its lead drug funded largely by the NIH ended early after achieving the primary endpoint. Then after momentarily rattling investors with a report on some serious side effects, the biotech bounced back with upbeat data from its Phase III for primary biliary cirrhosis, setting the stage for a regulatory filing. The bile acid analog--which mimics human bile acid and is an agonist for the farnesoid X receptor--is in development for PBC, nonalcoholic steatohepatitis and other liver and intestinal diseases.

For more:
Intercept grabs the spotlight at EASL, builds case for lead drug OCA
Intercept scores a PhIII win for lead drug following Friday night frights
Intercept shares dazzle after early success of PhIIb liver disease drug trial

Obeticholic acid (OCA), Intercept Pharmaceuticals
Read more on

Suggested Articles

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Gilead names Dickinson to CFO role; MedImmune CSO Herbst nabs CSO job at Pyxis; Checkmate picks up Wooldridge for CMO.

The readout is a key moment in the history of the drug and Mirati, shares in which have soared in the updraft created by data on Amgen’s rival asset.